卵圆孔未闭的治疗和反常栓塞风险量表临床应用研究进展

doi:10.3969/j.issn.1673-5765.2018.12.019

摘要/Abstract

摘要：

卒中已成为我国居民的第一位死亡原因，经全面检查仍无法找到明确病因的称之为隐源性卒中（cryptogenic stroke，CS），而卵圆孔未闭（patent foramen ovale，PFO）引起的反常栓塞是导致CS 最可能的原因。近几年对合并PFO的CS选择何种治疗方法一直存在争议，同时一种可以预测反常栓塞的最新量表，即反常栓塞风险量表（risk of paradoxical embolism，RoPE）也成为国内外很多学者研究的热点，本文对目前PFO治疗的研究以及RoPE在PFO中的临床应用进行综述。

文章导读： 卵圆孔未闭选择药物治疗还是封堵术治疗需根据患者的情况来选择，反常栓塞风险量表的提出有助于帮助临床医生判断卵圆孔未闭是否和栓塞有关。

关键词: 隐源性卒中; 卵圆孔未闭; 反常栓塞风险量表

Abstract:

Stroke is the first cause of death in China, and cryptogenic stroke (CS) is a special kind of ischemic stroke. The cause of stroke is still not determined even after a thorough examination, such stroke is called CS. Abnormal embolism caused by patent foramen ovale (PFO) is the most likely cause of CS. In recent years, the treatment methods of CS with PFO have long been controversial. At the same time, the Risk of Paradoxical Embolism (RoPE) score, a new scale which can predict abnormal embolism risk, has become a hot issue at home and abroad. This article reviewed the current research on PFO treatment and clinical application of RoPE scale in PFO.

Key words: Cryptogenic stroke; Patent foramen ovale; Risk of paradoxical embolism

范学慧，钟镝，陈洪苹，李国忠，赵秀丽. 卵圆孔未闭的治疗和反常栓塞风险量表临床应用研究进展[J]. 中国卒中杂志, 2018, 13(12): 1321-1326.

FAN Xue-Hui, ZHONG Di, CHEN Hong-Ping, LI Guo-Zhong, ZHAO Xiu-Li. Advance in Treatment of Patent Foramen Ovale and Clinical Application of Paradoxical Embolism Risk Scale[J]. Chinese Journal of Stroke, 2018, 13(12): 1321-1326.

参考文献

[1] Writing Group Members，MOZAFFARIAN

D，BENJAMIN E J，et al. Heart disease and

stroke statistics-2016 update：a report from the

American Heart Association[J/OL]. Circulation，

2016，133（4）：e38-e360. https：//doi.org/10.1161/

CIR.0000000000000350.

[2] HOMMA S，SACCO R L，DI TULLIO M R，et

al. Effect of medical treatment in stroke patients

with patent foramen ovale：patent foramen ovale in

Cryptogenic Stroke Study[J]. Circulation，2002，105

（22）：2625-2631.

[3] YAGHI S，ELKIND M S. Cryptogenic stroke：A

diagnostic challenge[J]. Neurol Clin Pract，2014，4

（5）：386-393.

[4] LECHAT P，MAS J L，LASCAULT G，et al.

Prevalence of patent foramen ovale in patients with

stroke[J]. N Engl J Med，1988，318（18）：1148-1152.

[5] THALER D E，DI ANGELANTONIO E，DI

TULLIO M R，et al. The risk of paradoxical

embolism（RoPE）study：initial description of the

completed database[J]. Int J Stroke，2013，8（8）：

612-619.

[6] ?ENADIM S，BOZKURT D，ÇABALAR M，et

al. The role of patent foramen ovale in cryptogenic

stroke[J]. Noro Psikiyatr Ars，2016，53（1）：63-66.

[7] KENT D M，RUTHAZER R，WEIMAR C，et al. An

index to identify stroke-related vs incidental patent

foramen ovale in cryptogenic stroke[J]. Neurology，

2013，81（7）：619-625.

[8] WINDECKER S，MEIER B. Is closure

recommended for patent foramen ovale and

cryptogenic stroke? Patent foramen ovale and

cryptogenic stroke：to close or not to close? Closure：

what else![J]. Circulation，2008，118（19）：1989-

1998.

[9] KITSIOS G D，DAHABREH I J，ABU DABRH A

M，et al. Patent foramen ovale closure and medical

treatments for secondary stroke prevention：a

systematic review of observational and randomized

evidence[J]. Stroke，2012，43（2）：422-431.

[10] KENT D M，DAHABREH I J，RUTHAZER R，et

al. Anticoagulant vs. antiplatelet therapy in patients

with cryptogenic stroke and patent foramen ovale：

an individual participant data meta-analysis[J]. Eur

Heart J，2015，36（35）：2381-2389.

[11] KERNAN W N，OVBIAGELE B，BLACK H R，et

al. Guidelines for the prevention of stroke in patients

with stroke and transient ischemic attack：a guideline

for healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke，

2014，45（7）：2160-2236.

[12] FORD M A，REEDER G S，LENNON R J，et

al. Percutaneous device closure of patent foramen

ovale in patients with presumed cryptogenic stroke

or transient ischemic attack：the Mayo Clinic

experience[J]. JACC Cardiovasc Interv，2009，2（5）：

404-411.

[13] STANCZAK L J，BERTOG S C，WUNDERLICH

N，et al. PFO closure with the Premere PFO closure

device：acute results and follow-up of 263 patients[J].

EuroIntervention，2012，8（3）：345-351.

[14] SIDDIQUI I F，MICHAELS A D. Percutaneous

patent foramen ovale closure using Helex and

Amplatzer devices without intraprocedural

echocardiographic guidance[J]. J Interv Cardiol，

2011，24（3）：271-277.

[15] MIRZAALI M，DOOLEY M，WYNNE D，et al.

Patent foramen ovale closure following cryptogenic

stroke or transient ischaemic attack：Long-term

follow-up of 301 cases[J]. Catheter Cardiovasc Interv，

2015，86（6）：1078-1084.

[16] MOON J，KANG W C，KIM S，et al. Comparison

of outcomes after device closure and medication

alone in patients with patent foramen ovale and

cryptogenic stroke in korean population[J]. Yonsei

Med J，2016，57（3）：621-625.

[17] AGARWAL S，BAJAJ N S，KUMBHANI D J，et al.

Meta-analysis of transcatheter closure versus medical

therapy for patent foramen ovale in prevention

of recurrent neurological events after presumed

paradoxical embolism[J]. JACC Cardiovasc Interv，

2012，5（7）：777-789.

[18] FREUND M A，REEDER G S，CABALKA A K，et

al. Percutaneous device closure of patent foramen

ovale for cryptogenic strokes/transient ischemic

attacks[J]. JACC Cardiovasc Interv，2012，5（11）：

1189.

[19] FURLAN A J，REISMAN M，MASSARO J，et al.

Closure or medical therapy for cryptogenic stroke

with patent foramen ovale[J]. N Engl J Med，2012，

366（11）：991-999.

[20] MEIER B，KALESAN B，MATTLE H P，et al.

Percutaneous closure of patent foramen ovale in

cryptogenic embolism[J]. N Engl J Med，2013，368（12）：1083-1091.

[21] SAVER J L，CARROLL J D，THALER D E，et al.

Long-term outcomes of patent foramen ovale closure

or medical therapy after stroke[J]. N Engl J Med，

2017，377（11）：1022-1032.

[22] SØNDERGAARD L，KASNER S E，RHODES J

F，et al. Patent foramen ovale closure or antiplatelet

therapy for cryptogenic stroke[J]. N Engl J Med，

2017，377（11）：1033-1042.

[23] MAS J L，DERUMEAUX G，GUILLON B，et al.

Patent foramen ovale closure or anticoagulation vs.

antiplatelets after stroke[J]. N Engl J Med，2017，377

（11）：1011-1021.

[24] ELMARIAH S，FURLAN A J，REISMAN M，et

al. Predictors of recurrent events in patients with

cryptogenic stroke and patent foramen ovale within

the CLOSURE I（Evaluation of the STARFlex

Septal Closure System in Patients With a Stroke

and/or Transient Ischemic Attack Due to Presumed

Paradoxical Embolism Through a Patent Foramen

Ovale）trial[J]. JACC Cardiovasc Interv，2014，7（8）：

913-920.

[25] THALER D E，RUTHAZER R，WEIMAR C，et

al. Recurrent stroke predictors differ in medically

treated patients with pathogenic vs. other PFOs[J].

Neurology，2014，83（3）：221-226.

[26] WESSLER B S，KENT D M，THALER D E，et

al. The RoPE Score and right-to-left shunt severity

by transcranial Doppler in the CODICIA Study[J].

Cerebrovasc Dis，2015，40（1-2）：52-58.

[27] MARIUCCI E，DONTI A，SALOMONE L，et al.

Recurrent stroke after transcatheter PFO closure in

cryptogenic stroke or tia：long-term follow-up[J/OL].

Cardiol Res Pract，2017，2017：9849425. https：//doi.

org/10.1155/2017/9849425.

[28] 郑华光，王伊龙，陈启东，等. 反常性栓塞风险量表

在合并卵圆孔未闭的隐源性卒中或短暂性脑缺血

发作患者中的应用[J]. 中国卒中杂志，2014，9（8）：

654-662.

[29] 麻姣姣，翟妮娜，杨柳，等. 隐源性脑梗死患者反常

性栓塞量表评分与右向左分流严重程度的关系[J].

西安交通大学学报（医学版），2018，39（2）：271-

275.

[30] LI X Q，YUAN P，MA W J，et al. Clinical analysis

of young and middle-aged stroke patients with patent

foramen ovale[J]. Zhonghua Yi Xue Za Zhi，2018，98

（19）：1507-1510.